A risk-benefit assessment of irinotecan in solid tumours.

This publication has 83 references indexed in Scilit:

• The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996
  Critical Reviews in Oncology/Hematology, 1996
• Characterisation and Clinical Management of CPT-11 (Irinotecan)-induced Adverse Events: The European Perspective
  European Journal Of Cancer, 1996
• Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine
  Cancer Chemotherapy and Pharmacology, 1995
• A Pharmacokinetic and Pharmacodynamic Analysis of CPT‐11 and Its Active Metabolite SN‐38
  Japanese Journal of Cancer Research, 1995
• Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system.
  1993
• Enhanced Antitumor Efficacy of a Combination of CPT‐11, a New Derivative of Camptothecin, and Cisplatin against Human Lung Tumor Xenografts
  Japanese Journal of Cancer Research, 1993
• CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.
  Journal of Clinical Oncology, 1992
• CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.
  Journal of Clinical Oncology, 1992
• Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer
  JNCI Journal of the National Cancer Institute, 1991
• Modification of the hydroxylactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity
  Journal of Medicinal Chemistry, 1989